ACE Inhibitors Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
ACE Inhibitors Market Size Forecast: How Large Could The Market Become By 2030?
The market for ACE inhibitors has experienced significant expansion over recent years. From $7.41 billion in 2025, it is projected to reach $7.84 billion by 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical growth has been driven primarily by a higher incidence of hypertension, greater public recognition of cardiovascular conditions, the launch of first-generation ACE inhibitors, an expanding elderly demographic, and progress in drug development technologies.
The ace inhibitors market is projected to experience robust expansion in the coming years, reaching an estimated $10.11 billion by 2030 with a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by several factors, including the rising demand for personalized medicine, the adoption of digital health technologies, growth in emerging markets, the creation of innovative ace inhibitor combinations, and the increasing prevalence of home healthcare services. Key trends shaping the market outlook include a focus on tailored hypertension care, the use of telemedicine and remote patient monitoring, ongoing efforts in combination therapy innovation, a higher availability of generic ace inhibitors, and a broader uptake of home-based healthcare solutions.
Download A Free Sample Report For Comprehensive Market Insights:
ACE Inhibitors Market Development Factors: Which Trends Are Supporting Demand?
The expansion of the ACE inhibitors market is being fueled by a rising prevalence of cardiac disorders. These conditions, which affect the heart and blood vessels, encompass coronary artery disease, heart failure, and arrhythmias among others. By inhibiting the angiotensin-converting enzyme, ACE blockers diminish vasoconstriction, sodium retention, and aldosterone secretion, thereby improving heart function. For example, in January 2024 the American Heart Association, a US-based nonprofit, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000, representing a 4.0% increase from 224.4 per 100,000 in 2023. As a result, the growing frequency of cardiac disorders is driving the ACE inhibitors market forward.
ACE Inhibitors Market Segment Landscape: Which Areas Lead Market Development?
The ace inhibitors market covered in this report is segmented –
1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users
Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium
ACE Inhibitors Market Transformation Trends: Which Innovations Are Driving Change?
Major players within the ACE inhibitor sector are increasingly prioritizing the introduction of generic drugs as a strategy to secure a competitive advantage in the marketplace. A generic drug is defined as a pharmaceutical product containing identical active ingredients, dosage form, strength, safety profile, route of administration, and therapeutic efficacy as its brand-name counterpart, yet it is generally offered at a reduced price following the expiration of the original patent. As an example, in August 2023, Pharmascience Inc., a pharmaceutical firm based in Canada, released pms-PERINDOPRIL-INDAPAMIDE, a generic medication designed for the primary management of mild to moderate essential hypertension (elevated blood pressure) in adult patients. This combination therapy consists of two active substances: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor that works to relax blood vessels, and indapamide, a chlorosulphamoyl diuretic that promotes the elimination of extra fluid and sodium from the body. Working together, these components synergistically achieve effective blood pressure reduction across a broad patient population. pms-PERINDOPRIL-INDAPAMIDE is supplied in several dosage strengths, specifically 2 mg, 4 mg, and 8 mg of perindopril erbumine, each combined with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.
ACE Inhibitors Market Industry Leaders And Market Competition
Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.
Access The Complete ACE Inhibitors Market Report:
ACE Inhibitors Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
